United Therapeutics Corporation UTHR shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for ...
Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (Liquidia ...
Innovation in drug-device combinations for administering Remodulin will likely help offset losses from generics, if approved. We believe both the already-approved Remunity pump and the Implantable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results